ATE280823T1 - Verfahren zur inaktivierung vom umhüllten viren in einem viruspräparat mit adenoviren - Google Patents

Verfahren zur inaktivierung vom umhüllten viren in einem viruspräparat mit adenoviren

Info

Publication number
ATE280823T1
ATE280823T1 AT99403194T AT99403194T ATE280823T1 AT E280823 T1 ATE280823 T1 AT E280823T1 AT 99403194 T AT99403194 T AT 99403194T AT 99403194 T AT99403194 T AT 99403194T AT E280823 T1 ATE280823 T1 AT E280823T1
Authority
AT
Austria
Prior art keywords
inactivation
adenoviruses
viral preparation
preparation
virus
Prior art date
Application number
AT99403194T
Other languages
English (en)
Inventor
David Gaillac
Michel Koehl
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE280823T1 publication Critical patent/ATE280823T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C12N2710/10363—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
AT99403194T 1998-12-21 1999-12-17 Verfahren zur inaktivierung vom umhüllten viren in einem viruspräparat mit adenoviren ATE280823T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9816147A FR2787465A1 (fr) 1998-12-21 1998-12-21 Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes

Publications (1)

Publication Number Publication Date
ATE280823T1 true ATE280823T1 (de) 2004-11-15

Family

ID=9534248

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99403194T ATE280823T1 (de) 1998-12-21 1999-12-17 Verfahren zur inaktivierung vom umhüllten viren in einem viruspräparat mit adenoviren

Country Status (11)

Country Link
US (2) US7026154B1 (de)
EP (1) EP1016711B1 (de)
JP (1) JP4459353B2 (de)
AT (1) ATE280823T1 (de)
AU (1) AU769121B2 (de)
CA (1) CA2292922C (de)
DE (1) DE69921435T2 (de)
DK (1) DK1016711T3 (de)
ES (1) ES2230820T3 (de)
FR (1) FR2787465A1 (de)
PT (1) PT1016711E (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003014338A1 (en) * 2001-08-02 2003-02-20 Anges Mg, Inc. Process for producing inactivated virus envelope
JP5322252B2 (ja) * 2001-12-20 2013-10-23 バヴァリアン・ノルディック・アクティーゼルスカブ 感染細胞からのポックスウイルスの採取および精製法
ATE500267T1 (de) 2003-07-21 2011-03-15 Transgene Sa Multifunktionelle cytokine
US20050197496A1 (en) * 2004-03-04 2005-09-08 Gtc Biotherapeutics, Inc. Methods of protein fractionation using high performance tangential flow filtration
AU2005229674B2 (en) * 2004-11-18 2010-11-04 Kedrion Melville Inc. Low concentration solvent/detergent process of immuneglobulin with pre-treatment
US20060130159A1 (en) * 2004-12-09 2006-06-15 Nick Masiello Method of purifying recombinant MSP 1-42 derived from Plasmodium falciparum
US7531632B2 (en) * 2006-02-16 2009-05-12 Gtc Biotherapeutics, Inc. Clarification of transgenic milk using depth filtration
CL2008000249A1 (es) 2007-01-30 2008-05-30 Transgene Sa Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus
AU2010206195B2 (en) 2009-01-20 2016-03-10 Transgene Sa Soluble ICAM-1 as biomarker for prediction of therapeutic response
ES2555858T3 (es) 2009-03-24 2016-01-11 Transgene Sa Biomarcador para el control de pacientes
PL2419728T3 (pl) 2009-04-17 2014-05-30 Transgene Sa Biomarker do monitorowania pacjentów
CN102483405B (zh) 2009-07-10 2015-12-02 特朗斯吉有限公司 用于选择患者的生物标志物及相关方法
RU2555346C2 (ru) 2009-08-07 2015-07-10 Трансген Са Композиция для лечения инфекции вирусом гепатита в
BR112012026095A2 (pt) 2010-04-14 2015-09-15 Emd Millipore Corp métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos.
KR101619865B1 (ko) 2010-07-30 2016-05-11 이엠디 밀리포어 코포레이션 크로마토그래피 매질
ES2811526T3 (es) 2010-12-30 2021-03-12 Lab Francais Du Fractionnement Glicoles como agentes de inactivación de patógenos
EP3587455A1 (de) 2012-10-23 2020-01-01 Emory University Gm-csf- und il-4-konjugate, zusammensetzungen und zugehörige verfahren
EP3188816B1 (de) 2014-09-02 2021-06-09 EMD Millipore Corporation Chromatographie-medum, bestehend aus diskreten porösen bündeln von nanofibrillen
EP3230299A1 (de) 2014-12-08 2017-10-18 EMD Millipore Corporation Mischbettionenaustauschadsorber
EP4523756A3 (de) 2015-02-13 2025-05-28 Transgene Immunotherapeutischer impfstoff und antikörperkombinationstherapie
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
US11690869B2 (en) * 2020-04-23 2023-07-04 Johnson & Johnson Consumer Inc. Methods of inhibiting enveloped viruses using low molecular weight hydrophobically modified polymers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2057191T5 (es) * 1989-01-13 2003-05-01 Mitsubishi Pharma Corp Metodo de produccion para una composicion que contiene proteinas.
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6281010B1 (en) * 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
DE19623293C2 (de) * 1996-06-11 1998-10-22 Biotest Pharma Gmbh Nicht-immunogene Faktor VIII-enthaltende Zusammensetzung und ein Verfahren zu ihrer Herstellung
AU5370598A (en) * 1996-12-13 1998-07-03 Schering Corporation Methods for purifying viruses
DE19709186C2 (de) * 1997-03-06 1999-10-14 Medigene Ag Filtrationsverfahren zur Trennung von Viren

Also Published As

Publication number Publication date
CA2292922A1 (fr) 2000-06-21
US7378265B2 (en) 2008-05-27
DE69921435D1 (de) 2004-12-02
EP1016711A1 (de) 2000-07-05
EP1016711B1 (de) 2004-10-27
DE69921435T2 (de) 2006-03-02
US7026154B1 (en) 2006-04-11
AU6535899A (en) 2000-06-22
US20060166345A1 (en) 2006-07-27
DK1016711T3 (da) 2005-03-07
AU769121B2 (en) 2004-01-15
FR2787465A1 (fr) 2000-06-23
JP4459353B2 (ja) 2010-04-28
ES2230820T3 (es) 2005-05-01
CA2292922C (fr) 2011-05-31
JP2000201673A (ja) 2000-07-25
PT1016711E (pt) 2005-02-28

Similar Documents

Publication Publication Date Title
ATE280823T1 (de) Verfahren zur inaktivierung vom umhüllten viren in einem viruspräparat mit adenoviren
AU7489687A (en) Translation of mrna
ATE188740T1 (de) Viruspartikel mit veraendertem wirtspektrum
ATE149355T1 (de) Verfahren zur inaktivierung von prionen
DE3680130D1 (de) Verfahren zur vireninaktivierung in gamma-globulin durch waermebehandlung.
DE3486160D1 (de) Modifizierte lebende pseudo-rabies-viren, diese enthaltende impfstoffe gegen pseudo-rabies, verfahren zur herstellung und verfahren zur verwendung derselben.
DE69201952D1 (de) Verwendung eines enzymhaltigen granulates und verfahren zur herstellung von einem pelletisierten futter.
DE69534801D1 (de) Neues lysin decarboxylase gen und verfahren zur herstellung von l-lysin
EP0864646A3 (de) Verfahren zur Inaktivierung von lipidumhüllten Viren
DE68928956D1 (de) Verfahren zur Herstellung von optisch aktivem 1,3-Butanediol
DE69514865D1 (de) Verfahren zur Herstellung von L-Asparaginsäure
DE69432158D1 (de) Verfahren zur Herstellung von optisch aktiven 2-Amino-1-phenylethanol Derivaten
DE59209794D1 (de) Verfahren zur Herstellung von Enzymzubereitungen
GB1488774A (en) Hepatitis b antigen and method of producing it
DE69005542D1 (de) Verfahren zur Herstellung von 3-Pentensäure.
DE69027569D1 (de) Verfahren zur Herstellung von Enynderivaten
ATE71110T1 (de) Verfahren zur reinigung eines proteins.
DE68915310D1 (de) Verfahren zur Herstellung von enantiomerischen homogenen Aminopyrrolidinyl-naphthyridin- und Quinoloncarbonsäuren.
FI880636A7 (fi) Menetelmä vaipallisten virusten inaktivoimiseksi solun avulla in vitro valmistetuissa proteiinivalmisteissa.
DE59004380D1 (de) Verfahren zur Herstellung von alpha-Fluoracrylsäurederivaten und neue 1,1-Difluor-2-halogenethyl-(halogen) methyl-ketone.
DE68910771D1 (de) Verfahren zur Herstellung von verbessertem Proteinhydrolysat.
EP0711159A4 (de) Verfahren und zusammensetzungen zur behandlung von asthma, arthereosklerose und entzuendlichen erkrankungen unter verwendung von optisch reinem (-)-zilenton
DE69109243D1 (de) Verfahren zur Herstellung von L-Tryptophan und L-Threonine.
DE59309002D1 (de) Verfahren zur Herstellung von 6-Chlor-(6H)-dibenz-(c,e)(1,2)-oxaphosphorin
DE69103913D1 (de) Verfahren zur Herstellung von Dodekandicarbonsäure.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1016711

Country of ref document: EP